Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) will present at the 6th Macrophage-Directed Therapies Summit in Boston from October 1-
The company will showcase its Chimeric Bait Receptor (CBR) platform, an advanced immunotherapy that programs innate immune cells to target specific cancers and viral infections.
The presentation will highlight the CBR platform's application in treating rare cancers.